2:56 AM
 | 
Nov 12, 2018
 |  BC Extra  |  Financial News

Swiss cancer play Amal eyes clinic following €21.2M tranche

Cancer vaccine company Amal Therapeutics S.A. (Geneva, Switzerland) closed the second and final tranche of its series B round at €21.2 million ($24 million), bringing the...

Read the full 108 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >